Key result
Parecoxib sodium demonstrated a combined incidence of erosions/ulcers comparable to placebo and lower than ketorolac.
Why the study?
Does parecoxib sodium improve gastrointestinal safety compared to ketorolac or placebo in healthy adults?
RCT (n=123)
double-blind
randomized
Yes
Does parecoxib sodium improve gastrointestinal safety compared to ketorolac or placebo in healthy adults?
Parecoxib sodium demonstrates a gastrointestinal safety profile superior to ketorolac and comparable to placebo in healthy subjects.
Answers are grounded in this paper and cite their sources.
Supports preferring parecoxib over ketorolac to reduce GI risk; confirms placebo-comparable safety in this RCT.
BACKGROUND: The gastrointestinal safety of the novel injectable cyclooxygenase-2 selective inhibitor, parecoxib sodium, was compared with the nonselective nonsteroidal anti-inflammatory drug, ketorolac, and placebo in healthy subjects. STUDY: In a multicenter, randomized, double-blind, placebo-controlled design, 123 adults with endoscopically-confirmed normal upper gastrointestinal mucosae received parecoxib sodium 40 mg twice daily (7 days); placebo (2 days) followed by ketorolac 30 mg 4 times daily (5 days); or placebo (7 days) (each group n = 41). Posttreatment endoscopy scores were analyzed at 3 levels of severity: ulcers (scores of 7), > or =11 erosions/ulcers (scores of 5-7), and any erosions/ulcers (scores of 3-7). RESULTS: No subjects treated with parecoxib sodium or placebo developed gastroduodenal ulcers or > or =11 erosions/ulcers. Parecoxib sodium was comparable to placebo with respect to the combined incidence of erosions/ulcers (12% vs. 7%, P = 0.419). In contrast, in the ketorolac group, 11 (28%) subjects developed ulcers, 19 (48%) subjects developed > or =11 gastroduodenal erosions/ulcers, and the rate of combined ulcers/erosions was 85% (P < 0.001 vs. placebo and parecoxib sodium). CONCLUSIONS: Parecoxib sodium 40 mg twice daily for 7 days has a gastrointestinal safety profile superior to ketorolac 30 mg 4 times daily for 5 days, and comparable to placebo.
No takes yet. Share an insight, caveat, or question.
Harris et al. (2004) conducted an RCT in Healthy subjects (n=123). Parecoxib sodium vs. Placebo and ketorolac was evaluated on Combined incidence of erosions/ulcers (p=0.419). Parecoxib sodium demonstrated a combined incidence of erosions/ulcers comparable to placebo and lower than ketorolac.
Synapse has enriched 10 related papers. Consider them for comparative context: